Cargando…

Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis

OBJECTIVES: To compare real-world effectiveness of two adaptive treatment strategies of disease-modifying antirheumatic drugs (DMARDs) in treating children with newly diagnosed polyarticular course juvenile idiopathic arthritis (pcJIA): early aggressive use of biologic DMARDs (bDMARDs) in combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Bin, Qiu, Tingting, Chen, Chen, Zhang, Yin, Seid, Michael, Lovell, Dan, Brunner, Hermine I, Morgan, Esi M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Paediatric Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003379/ https://www.ncbi.nlm.nih.gov/pubmed/32396520 http://dx.doi.org/10.1136/rmdopen-2019-001091

Ejemplares similares

Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis
por: Lovell, Daniel J, et al.
Publicado: (2021)

Children with extended oligoarticular and polyarticular juvenile idiopathic arthritis have alterations in B and T follicular cell subsets in peripheral blood and a cytokine profile sustaining B cell activation
por: Tomé, Catarina, et al.
Publicado: (2023)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
por: Gerss, Joachim, et al.
Publicado: (2022)

Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Ravelli, Angelo, et al.
Publicado: (2016)

Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal
por: Leong, Jing Yao, et al.
Publicado: (2019)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Genomic risk scores for juvenile idiopathic arthritis and its subtypes
por: Cánovas, Rodrigo, et al.
Publicado: (2020)

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2015)

Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
por: Horne, AnnaCarin, et al.
Publicado: (2019)

Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritis
por: Backström, Maria, et al.
Publicado: (2019)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
por: Alongi, Alessandra, et al.
Publicado: (2022)

Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
por: Montag, Laura J, et al.
Publicado: (2022)

Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases
por: Oliveira Ramos, Filipa, et al.
Publicado: (2021)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

Antibiotic exposure in prenatal and early life and risk of juvenile idiopathic arthritis: a nationwide register-based cohort study
por: Hestetun, Sigrid, et al.
Publicado: (2023)

Development and reliability of a novel ultrasonographic joint-specific scoring system for synovitis with reference atlas for patients with juvenile idiopathic arthritis
por: Sande, Nina Krafft, et al.
Publicado: (2021)

Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis
por: Macaraeg, Marci, et al.
Publicado: (2023)

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
por: Woerner, A, et al.
Publicado: (2015)

Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms
por: López-Isac, Elena, et al.
Publicado: (2021)

Brief Report: The Genetic Profile of Rheumatoid Factor–Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis
por: Hinks, Anne, et al.
Publicado: (2018)

Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis
por: La, Céline, et al.
Publicado: (2021)

Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage
por: Oliveira-Ramos, Filipa, et al.
Publicado: (2016)

Whole Blood Gene Expression Profiling Predicts Therapeutic Response at Six Months in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Jiang, Kaiyu, et al.
Publicado: (2014)

Associations between power Doppler ultrasound findings and B-mode synovitis and clinical arthritis in juvenile idiopathic arthritis using a standardised scanning approach and scoring system
por: Sande, Nina Krafft, et al.
Publicado: (2023)

Malignancy incidence in 5294 patients with juvenile arthritis
por: Zahedi Niaki, Omid, et al.
Publicado: (2016)

High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti–Tumor Necrosis Factor Therapy
por: Mor‐Vaknin, Nirit, et al.
Publicado: (2018)

Procedures for the content, conduct and format of EULAR/PReS paediatric musculoskeletal ultrasound courses
por: Magni-Manzoni, Silvia, et al.
Publicado: (2022)

Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
por: Kimura, Yukiko, et al.
Publicado: (2021)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Juvenile Idiopathic Arthritis in the Era of International Cooperation
por: Uziel, Yosef
Publicado: (2017)

Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland
por: Burkard, Theresa, et al.
Publicado: (2022)

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study
por: Tappeiner, Christoph, et al.
Publicado: (2018)

Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities
por: Peterman, Nicholas J, et al.
Publicado: (2022)

Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives
por: Ambler, William G., et al.
Publicado: (2022)

Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis
por: Jones, Nicholas T, et al.
Publicado: (2023)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ev6kb63gso0jvs72jv7v1s0r8m